Wedbush Lowers Voyager Therapeutics Price Target to $8 Amid Market Review

Wedbush analyst Yun Zhong has lowered the price target for Voyager Therapeutics (VYGR) to $8 from $9, a decrease of 11.11%. Despite this, Voyager remains rated "Outperform" by Wedbush, indicating continued confidence in the company's market potential. The average target price for VYGR is $16.00 with an upside of 370.59% from the current price.

Voyager Therapeutics, Inc. (NASDAQ: VYGR) has seen a notable shift in analyst sentiment and price target adjustments. The company has received a "Buy" recommendation from eight analysts, with an average one-year price target of $13.39 [1]. However, recent institutional inflows and earnings reports have sparked interest and concern among investors.

Institutional investors have significantly increased their stakes in Voyager Therapeutics. Allspring Global Investments grew its position by 53.8% in the first quarter of 2025 [1]. Additionally, several other institutional investors have bolstered their holdings, indicating confidence in the company's potential. However, shares of VYGR have traded down $0.23 during trading on Wednesday, reaching $2.96, marking a 7.2% decline from its previous close [1].

The company reported earnings of $0.53 per share for the quarter ended May 6, 2025, missing the consensus estimate of $0.35 per share by $0.18 [2]. This quarterly report represents an earnings surprise of -18.75%, with revenues of $6.47 million falling short of analyst estimates by 55.43% [2]. The company's negative net margin of 126.49% and negative return on equity of 27.36% underscore the challenges it faces.

Despite the recent earnings miss and stock decline, Wedbush analyst Yun Zhong has lowered the price target for VYGR to $8 from $9, a decrease of 11.11%. However, the company remains rated "Outperform" by Wedbush, indicating continued confidence in its market potential [3]. The average target price for VYGR is $16.00 with an upside of 370.59% from the current price [3].

Investors should closely monitor Voyager Therapeutics' earnings outlook and management's commentary on the earnings call. The company's near-term performance may depend on its ability to meet or exceed earnings estimates and execute on its clinical pipeline, which includes VY-TAU01, an anti-tau antibody program for the treatment of Alzheimer's disease [1].

References:
[1] https://www.marketbeat.com/instant-alerts/voyager-therapeutics-inc-nasdaqvygr-given-average-recommendation-of-buy-by-analysts-2025-07-30/
[2] https://www.nasdaq.com/articles/voyager-therapeutics-vygr-reports-q2-loss-lags-revenue-estimates
[3] https://www.marketbeat.com/instant-alerts/voyager-therapeutics-inc-nasdaqvygr-given-average-recommendation-of-buy-by-analysts-2025-07-30/